Literature DB >> 26447027

Expression of ezrin in oral squamous cell carcinoma: Prognostic impact and clinicopathological correlations.

Ali-Farid Safi1, Hans-Joachim Nickenig1, Daniel Rothamel1, Matthias Zirk1, Oliver Thiele1, Andrea Grandoch1, Martin Scheer2, Max Zinser1, Joachim Zöller1, Uta Drebber3, Matthias Kreppel4.   

Abstract

INTRODUCTION: There have been few investigations into the effects of ezrin expression in oral squamous cell carcinoma (OSCC). The aim of this study was to analyze the influence of ezrin expression on the prognosis of patients with OSCC.
MATERIALS AND METHODS: Eighty patients were included in the retrospective study. Expression and localization of ezrin were evaluated using immunohistochemistry. Associations were identified using χ² tests. Prognostic factors were identified by univariate and multivariate analysis.
RESULTS: Seventy-six (95%) patients showed ezrin expression. Ezrin expression had a significant impact on overall survival (OS) (p < 0.001). With increasing expression, the 5-year OS rate dropped from 100% for ezrin-negative patients to 47% for patients with high expression. Multivariate analysis confirmed the significant influence of ezrin expression on OS (p = 0.011). Cytoplasmic localization of ezrin led to a significantly lower survival rate in comparison with membranous expression.
CONCLUSIONS: Ezrin may serve as a biomarker that predicts biologically aggressive behavior of OSCC and hence improves therapeutic techniques and the prognosis of patients affected with the disease.
Copyright © 2015 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomarker; ERM proteins; Ezrin; Oral cancer; Prognosis

Mesh:

Substances:

Year:  2015        PMID: 26447027     DOI: 10.1016/j.jcms.2015.08.011

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  4 in total

1.  A novel histopathological scoring system for patients with oral squamous cell carcinoma.

Authors:  Ali-Farid Safi; Kathrin Grochau; Uta Drebber; Volker Schick; Oliver Thiele; Tim Backhaus; Hans-Joachim Nickenig; Joachim E Zöller; Matthias Kreppel
Journal:  Clin Oral Investig       Date:  2019-01-23       Impact factor: 3.573

2.  Risk factors associated with the mortality rate of oral squamous cell carcinoma patients: A 10-year retrospective study.

Authors:  Paras Ahmad; Rubbia Nawaz; Maria Qurban; Gul Muhammad Shaikh; Roshan Noor Mohamed; Anil Kumar Nagarajappa; Jawaad Ahmed Asif; Mohammad Khursheed Alam
Journal:  Medicine (Baltimore)       Date:  2021-09-10       Impact factor: 1.817

Review 3.  Platelet CLEC2-Podoplanin Axis as a Promising Target for Oral Cancer Treatment.

Authors:  Byeong-Oh Hwang; Se-Young Park; Eunae Sandra Cho; Xianglan Zhang; Sun Kyoung Lee; Hyung-Joon Ahn; Kyung-Soo Chun; Won-Yoon Chung; Na-Young Song
Journal:  Front Immunol       Date:  2021-12-15       Impact factor: 7.561

4.  Moesin Serves as Scaffold Protein for PD-L1 in Human Uterine Cervical Squamous Carcinoma Cells.

Authors:  Rina Doukuni; Takuro Kobori; Chihiro Tanaka; Mayuka Tameishi; Yoko Urashima; Takuya Ito; Tokio Obata
Journal:  J Clin Med       Date:  2022-07-01       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.